342 related articles for article (PubMed ID: 33963091)
1. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
[TBL] [Abstract][Full Text] [Related]
2. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
[TBL] [Abstract][Full Text] [Related]
4. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.
Gómez-García de la Banda M; Amaddeo A; Khirani S; Pruvost S; Barnerias C; Dabaj I; Bénézit A; Durigneux J; Carlier RY; Desguerre I; Quijano-Roy S; Fauroux B
Pediatr Pulmonol; 2021 Jan; 56(1):299-306. PubMed ID: 33118682
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
6. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
7. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy - A single-center retrospective study.
Heitschmidt L; Pichlmaier L; Eckerland M; Steindor M; Olivier M; Fuge I; Kölbel H; Hirtz R; Stehling F
Eur J Paediatr Neurol; 2021 Mar; 31():88-91. PubMed ID: 33711791
[TBL] [Abstract][Full Text] [Related]
10. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
11. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
13. An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy.
Bjelica B; Wohnrade C; Osmanovic A; Schreiber-Katz O; Petri S
J Neurol; 2023 Jul; 270(7):3616-3622. PubMed ID: 37062018
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
[TBL] [Abstract][Full Text] [Related]
15. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
17. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
[TBL] [Abstract][Full Text] [Related]
18. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
20. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
